share_log

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/11/13 20:48

Moomoo AI 已提取核心信息

Cybin Inc. reported a net loss of $57.2M for Q2 2024, compared to $11.9M in Q2 2023, primarily due to increased research expenses of $9.1M and general administrative costs of $15.7M. Share-based compensation significantly increased to $33.5M from $1.4M year-over-year.The company maintains a strong financial position with cash reserves of $154.3M as of September 30, 2024, down from $209M at March 31, 2024. Research expenses focused on advancement of development programs at $5.8M, while capital market expenses reached $9.6M. The company has commitments for various studies worth up to $60.3M expected to be paid within 18 months.During the quarter, Cybin completed a 1-for-38 share consolidation and granted new stock options to employees and executives. The company continues to advance its clinical-stage neuropsychiatric therapies, with ongoing development of delivery mechanisms and novel compounds for psychiatric and neurological conditions.
Cybin Inc. reported a net loss of $57.2M for Q2 2024, compared to $11.9M in Q2 2023, primarily due to increased research expenses of $9.1M and general administrative costs of $15.7M. Share-based compensation significantly increased to $33.5M from $1.4M year-over-year.The company maintains a strong financial position with cash reserves of $154.3M as of September 30, 2024, down from $209M at March 31, 2024. Research expenses focused on advancement of development programs at $5.8M, while capital market expenses reached $9.6M. The company has commitments for various studies worth up to $60.3M expected to be paid within 18 months.During the quarter, Cybin completed a 1-for-38 share consolidation and granted new stock options to employees and executives. The company continues to advance its clinical-stage neuropsychiatric therapies, with ongoing development of delivery mechanisms and novel compounds for psychiatric and neurological conditions.
Cybin Inc.报告2024年第二季度净亏损为5720万美元，较2023年第二季度的1190万美元大幅增加，主要由于研究费用增加了910万美元和行政成本增加了1570万美元。基于股份的薪酬从去年同期的140万美元显著增加至3350万美元。截至2024年9月30日，公司保持强劲的财务状况，现金储备为15430万美元，较2024年3月31日的20900万美元下降。研究费用主要用于开发项目，支出为580万美元，而资本市场费用达到了960万美元。公司承诺进行多项研究，总价值可达6030万美元，预计将在18个月内支付。在本季度，Cybin完成了1拆38的股份合并，并向员工和高管授予了新的股票期权。公司继续推进其临床阶段的神经精神治疗，正在开发用于精神和神经疾病的输送机制和新型化合物。
Cybin Inc.报告2024年第二季度净亏损为5720万美元，较2023年第二季度的1190万美元大幅增加，主要由于研究费用增加了910万美元和行政成本增加了1570万美元。基于股份的薪酬从去年同期的140万美元显著增加至3350万美元。截至2024年9月30日，公司保持强劲的财务状况，现金储备为15430万美元，较2024年3月31日的20900万美元下降。研究费用主要用于开发项目，支出为580万美元，而资本市场费用达到了960万美元。公司承诺进行多项研究，总价值可达6030万美元，预计将在18个月内支付。在本季度，Cybin完成了1拆38的股份合并，并向员工和高管授予了新的股票期权。公司继续推进其临床阶段的神经精神治疗，正在开发用于精神和神经疾病的输送机制和新型化合物。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间